ReviewFrontiers in immunology2025
Mechanistic insights into Nrf2-driven pathogenesis and therapeutic targeting in spinal cord injury.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DHCR24 in cholesterol metabolism and diseases of the nervous system.Lipids in health and disease · 2026Review
- circ_0044235 exacerbates neuroinflammation and apoptosis following spinal cord injury by targeting miR-338-5p.Journal of orthopaedic surgery and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a traumatic disease of the central nervous system that can result in significant tissue damage and neurological dysfunction. The pathophysiological process of SCI encompasses both primary and secondary injuries, involving various pathological mechanisms such as oxidative stress, inflammation, autophagy, ferroptosis, and mitochondrial dysfunction. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a neuroprotective transcription factor intricately linked to these pathological processes. Upon exposure to external stimuli, Nrf2 undergoes increased nuclear transcription, regulating the expression of various antioxidant genes and directly modulating genes associated with the aforementioned pathological mechanisms to counteract the resultant alterations. Substantial evidence suggests that Nrf2 may be a potential therapeutic target for SCI. Activation of the Nrf2-related signaling pathway effectively inhibits neuronal death following SCI and promotes the recovery of multiple neurological functions. This review provides an overview of recent research on SCI, examines the physiological roles and mechanisms of Nrf2 in SCI, and explores therapeutic strategies targeting this signaling pathway, including non-coding RNAs, natural and synthetic compounds, and other treatments for SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.